Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 14

1.

Combined HDAC and BET Inhibition Enhances Melanoma Vaccine Immunogenicity and Efficacy.

Badamchi-Zadeh A, Moynihan KD, Larocca RA, Aid M, Provine NM, Iampietro MJ, Kinnear E, Penaloza-MacMaster P, Abbink P, Blass E, Tregoning JS, Irvine DJ, Barouch DH.

J Immunol. 2018 Nov 1;201(9):2744-2752. doi: 10.4049/jimmunol.1800885. Epub 2018 Sep 24.

2.

Immunogenicity and Cross-Reactivity of Rhesus Adenoviral Vectors.

Iampietro MJ, Larocca RA, Provine NM, Abbink P, Kang ZH, Bricault CA, Barouch DH.

J Virol. 2018 May 14;92(11). pii: e00159-18. doi: 10.1128/JVI.00159-18. Print 2018 Jun 1.

3.

Adenovirus serotype 5 vaccine vectors trigger IL-27-dependent inhibitory CD4+ T cell responses that impair CD8+ T cell function.

Larocca RA, Provine NM, Aid M, Iampietro MJ, Borducchi EN, Badamchi-Zadeh A, Abbink P, Ng'ang'a D, Bricault CA, Blass E, Penaloza-MacMaster P, Stephenson KE, Barouch DH.

Sci Immunol. 2016 Nov;1(5). pii: eaaf7643. doi: 10.1126/sciimmunol.aaf7643. Epub 2016 Nov 4.

4.

Development of novel replication-defective lymphocytic choriomeningitis virus vectors expressing SIV antigens.

Penaloza MacMaster P, Shields JL, Alayo QA, Cabral C, Jimenez J, Mondesir J, Chandrashekar A, Cabral JM, Lim M, Iampietro MJ, Provine NM, Bricault CA, Seaman M, Orlinger K, Aspoeck A, Fuhrmann G, Lilja AE, Monath T, Mangeat B, Pinschewer DD, Barouch DH.

Vaccine. 2017 Jan 3;35(1):1-9. doi: 10.1016/j.vaccine.2016.11.063. Epub 2016 Nov 26.

5.

Vaccine protection against Zika virus from Brazil.

Larocca RA, Abbink P, Peron JP, Zanotto PM, Iampietro MJ, Badamchi-Zadeh A, Boyd M, Ng'ang'a D, Kirilova M, Nityanandam R, Mercado NB, Li Z, Moseley ET, Bricault CA, Borducchi EN, Giglio PB, Jetton D, Neubauer G, Nkolola JP, Maxfield LF, De La Barrera RA, Jarman RG, Eckels KH, Michael NL, Thomas SJ, Barouch DH.

Nature. 2016 Aug 25;536(7617):474-8. Epub 2016 Jun 28.

6.

Construction and evaluation of novel rhesus monkey adenovirus vaccine vectors.

Abbink P, Maxfield LF, Ng'ang'a D, Borducchi EN, Iampietro MJ, Bricault CA, Teigler JE, Blackmore S, Parenteau L, Wagh K, Handley SA, Zhao G, Virgin HW, Korber B, Barouch DH.

J Virol. 2015 Feb;89(3):1512-22. doi: 10.1128/JVI.02950-14. Epub 2014 Nov 19.

7.

Alternative serotype adenovirus vaccine vectors elicit memory T cells with enhanced anamnestic capacity compared to Ad5 vectors.

Penaloza-MacMaster P, Provine NM, Ra J, Borducchi EN, McNally A, Simmons NL, Iampietro MJ, Barouch DH.

J Virol. 2013 Feb;87(3):1373-84. doi: 10.1128/JVI.02058-12. Epub 2012 Nov 14.

8.

First-in-human evaluation of the safety and immunogenicity of a recombinant adenovirus serotype 26 HIV-1 Env vaccine (IPCAVD 001).

Baden LR, Walsh SR, Seaman MS, Tucker RP, Krause KH, Patel A, Johnson JA, Kleinjan J, Yanosick KE, Perry J, Zablowsky E, Abbink P, Peter L, Iampietro MJ, Cheung A, Pau MG, Weijtens M, Goudsmit J, Swann E, Wolff M, Loblein H, Dolin R, Barouch DH.

J Infect Dis. 2013 Jan 15;207(2):240-7. doi: 10.1093/infdis/jis670. Epub 2012 Nov 2.

9.

Characterization of humoral and cellular immune responses elicited by a recombinant adenovirus serotype 26 HIV-1 Env vaccine in healthy adults (IPCAVD 001).

Barouch DH, Liu J, Peter L, Abbink P, Iampietro MJ, Cheung A, Alter G, Chung A, Dugast AS, Frahm N, McElrath MJ, Wenschuh H, Reimer U, Seaman MS, Pau MG, Weijtens M, Goudsmit J, Walsh SR, Dolin R, Baden LR.

J Infect Dis. 2013 Jan 15;207(2):248-56. doi: 10.1093/infdis/jis671. Epub 2012 Nov 2.

10.

Vaccination with adenovirus serotypes 35, 26, and 48 elicits higher levels of innate cytokine responses than adenovirus serotype 5 in rhesus monkeys.

Teigler JE, Iampietro MJ, Barouch DH.

J Virol. 2012 Sep;86(18):9590-8. doi: 10.1128/JVI.00740-12. Epub 2012 Jul 11.

11.

Accelerated heterologous adenovirus prime-boost SIV vaccine in neonatal rhesus monkeys.

Liu J, Li H, Iampietro MJ, Barouch DH.

J Virol. 2012 Aug;86(15):7829-35. doi: 10.1128/JVI.00512-12. Epub 2012 May 16.

12.

Vaccine protection against acquisition of neutralization-resistant SIV challenges in rhesus monkeys.

Barouch DH, Liu J, Li H, Maxfield LF, Abbink P, Lynch DM, Iampietro MJ, SanMiguel A, Seaman MS, Ferrari G, Forthal DN, Ourmanov I, Hirsch VM, Carville A, Mansfield KG, Stablein D, Pau MG, Schuitemaker H, Sadoff JC, Billings EA, Rao M, Robb ML, Kim JH, Marovich MA, Goudsmit J, Michael NL.

Nature. 2012 Jan 4;482(7383):89-93. doi: 10.1038/nature10766.

13.

Adenovirus serotype 5 neutralizing antibodies target both hexon and fiber following vaccination and natural infection.

Bradley RR, Lynch DM, Iampietro MJ, Borducchi EN, Barouch DH.

J Virol. 2012 Jan;86(1):625-9. doi: 10.1128/JVI.06254-11. Epub 2011 Nov 9.

14.

Adenovirus serotype 5-specific neutralizing antibodies target multiple hexon hypervariable regions.

Bradley RR, Maxfield LF, Lynch DM, Iampietro MJ, Borducchi EN, Barouch DH.

J Virol. 2012 Jan;86(2):1267-72. doi: 10.1128/JVI.06165-11. Epub 2011 Nov 9.

Supplemental Content

Loading ...
Support Center